Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock NewsStockTitan·Jul 15 at 09:00 PMTBPH+6.00%ZYME+2.14%
14:43 ET$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATKprnewswire·Jul 9 at 01:45 PMIRDM+3.43%LCII-4.63%
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by AnalystsMarket Beat·Jul 9 at 05:29 AMTBPH+6.00%JPM+2.05%
Major Theravance Biopharma Investor Makes Notable Stock MoveTip Ranks·Jul 8 at 09:02 PMTBPH+6.00%ZYME+2.14%
Theravance Biopharma 10% owner Eli Samaha disposes of USD 119,359 in common sharesPUBT·Jul 8 at 03:14 PMTBPH+6.00%
Theravance Biopharma 10% owner Eli Samaha sells 336,697 common shares worth $5.78 millionPUBT·Jul 1 at 06:34 PMTBPH+6.00%
Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37Tip Ranks·Jun 30 at 04:55 AMZYME+2.14%TBPH+6.00%
Zymeworks agrees to buy Theravance Biopharma for $929mPharmaceutical Business Review·Jun 30 at 03:00 AMTBPH+6.00%ZYME+2.14%
Zymeworks to acquire Theravance Biopharma for USD 17 per share in USD 929 million dealPUBT·Jun 29 at 05:00 AMTBPH+6.00%ZYME+2.14%
